Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Steele

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Biochemistry|February 16, 2018
Inhibitor Bound Dengue NS2B-NS3pro Reveals Multiple Dynamic Binding ModesAlan C Gibbs, Ruth Steele, Gaohua Liu, et al.
Heliyon|January 2, 2023
Integrative structural and functional analysis of human malic enzyme 3: A potential therapeutic target for pancreatic cancerTsehai A J Grell, Mark Mason, Aaron A Thompson, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 5, 2022
Identification of Two Non-Peptidergic Small Molecule Inhibitors of CBX2 Binding to K27 Trimethylated OligonucleosomesLukas Lercher, Nina Simon, Andreas Bergmann, et al.
Nature Biotechnology|October 7, 2025
Folding-mediated secretion of pure bispecific antibodiesCholpon Tilegenova, Tun Liu, Qian Zhao, et al.
Nature Biotechnology|October 29, 2025
Author Correction: Folding-mediated secretion of pure bispecific antibodiesCholpon Tilegenova, Tun Liu, Qian Zhao, et al.
Scientific Reports|July 30, 2024
JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humansAnne M Fourie, Xiaoli Cheng, Leon Chang, et al.
Frontiers in Oncology|June 1, 2012
Family history of cancer in benign brain tumor subtypes versus gliomasQuinn T Ostrom, Christopher McCulloh, Yanwen Chen, et al.
Cell|January 17, 2026
Human genetics guides the discovery of CARD9 inhibitors with anti-inflammatory activityJason S Rush, Joshua D Wertheimer, Steven D Goldberg, et al.
Frontiers in Immunology|March 27, 2025
Guselkumab binding to CD64<sup>+</sup> IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signalingKacey L Sachen, Deepa Hammaker, Indra Sarabia, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biochemistry|February 16, 2018
Inhibitor Bound Dengue NS2B-NS3pro Reveals Multiple Dynamic Binding ModesAlan C Gibbs, Ruth Steele, Gaohua Liu, et al.
Heliyon|January 2, 2023
Integrative structural and functional analysis of human malic enzyme 3: A potential therapeutic target for pancreatic cancerTsehai A J Grell, Mark Mason, Aaron A Thompson, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 5, 2022
Identification of Two Non-Peptidergic Small Molecule Inhibitors of CBX2 Binding to K27 Trimethylated OligonucleosomesLukas Lercher, Nina Simon, Andreas Bergmann, et al.
Nature Biotechnology|October 7, 2025
Folding-mediated secretion of pure bispecific antibodiesCholpon Tilegenova, Tun Liu, Qian Zhao, et al.
Nature Biotechnology|October 29, 2025
Author Correction: Folding-mediated secretion of pure bispecific antibodiesCholpon Tilegenova, Tun Liu, Qian Zhao, et al.
Scientific Reports|July 30, 2024
JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humansAnne M Fourie, Xiaoli Cheng, Leon Chang, et al.
Frontiers in Oncology|June 1, 2012
Family history of cancer in benign brain tumor subtypes versus gliomasQuinn T Ostrom, Christopher McCulloh, Yanwen Chen, et al.
Cell|January 17, 2026
Human genetics guides the discovery of CARD9 inhibitors with anti-inflammatory activityJason S Rush, Joshua D Wertheimer, Steven D Goldberg, et al.
Frontiers in Immunology|March 27, 2025
Guselkumab binding to CD64<sup>+</sup> IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signalingKacey L Sachen, Deepa Hammaker, Indra Sarabia, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Pageof 2